An observational study in Multiple Sclerosis, Relapsing-Remitting, sponsored by Hoffmann-La Roche. Completed at 18 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-25.
Sponsored by Hoffmann-La Roche · Observational
This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments (DMT) in routine clinical practice.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 223 is above the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months
Exclusion Criteria:
Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
Percentage of Participants with Serious Adverse Events (Severe Life-Threatening or Less Severe)
Time frame: Up to 3 months
Percentage of Participants With DMT Administration Schedule Preferences
Time frame: Up to 3 months
Percentage of Participants With DMT Route of Administration Preferences
Time frame: Up to 3 months
DMT Efficacy Based on Annualized Relapse Rate
Time frame: Up to 3 months
Participants Education Level
Time frame: Baseline
Participants Employment Status
Time frame: Baseline
Participants RRMS Disease Duration
Time frame: Baseline
Number of Relapses of RRMS in Last 2 Years
Time frame: Baseline
Duration since Last Relapse of RRMS
Time frame: Baseline
Participants Current DMT for RRMS
Time frame: Baseline
Number of Previous DMTs Taken Prior to Switch to Current DMT
Time frame: Baseline
Expanded Disability Status Scale (EDSS) Score
Time frame: Up to 3 months
Health-Related Quality of Life Assessment Using Euro-Quality of Life 5 Dimension Questionnaire (EQ-5D) Scale Score
Time frame: Up to 3 months
Participant's Role in Decision Making measured by the Shared Decision Making Questionnaire 9-item version (SDM-Q-9) Score
Time frame: Up to 3 months
Cognitive performance as measured by the Medical Outcomes Study Cognitive Functioning Scale (MOS Cog-R) Score
Time frame: Up to 3 months
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche